Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ORIC | PRESS-RELEASE | neutral | 2/10 | ORIC Pharmaceuticals announced the grant of stock options and restricted stock units to a new non-executive employee as | Apr 3, 2026 |
| AEON | PRESS-RELEASE | bearish | 7/10 | AEON Biopharma received a notice from NYSE American that it is now non-compliant with an additional listing standard due | Apr 3, 2026 |
| NTLA | PRESS-RELEASE | neutral | 2/10 | Intellia Therapeutics granted inducement RSUs covering 67,150 shares to 13 new employees outside its shareholder-approve | Apr 3, 2026 |
| SYRE | PRESS-RELEASE | neutral | 3/10 | Spyre Therapeutics granted stock options to purchase 70,200 shares to five non-executive employees as inducement awards | Apr 3, 2026 |
| IBO | PRESS-RELEASE | bearish | 8/10 | Impact BioMedical (IBO) disclosed that its 2025 audit opinion includes a 'going concern' qualification, signaling substa | Apr 3, 2026 |
| DNLI | PRESS-RELEASE | mixed | 6/10 | Denali Therapeutics announced that Takeda has terminated their collaboration on DNL593, an investigational therapy for f | Apr 3, 2026 |
| BCAX | PRESS-RELEASE | neutral | 2/10 | Bicara Therapeutics granted a stock option to purchase 44,175 shares to a new employee as an inducement to join the comp | Apr 3, 2026 |
| BCDA | PRESS-RELEASE | bullish | 8/10 | BioCardia submitted clinical data from its CardiAMP HF trial to the FDA and plans to meet with the agency this quarter t | Apr 2, 2026 |
| ENTX | PRESS-RELEASE | mixed | 6/10 | Entera Bio (ENTX) announced a $10.0 million private placement led by BVF Partners, issuing 7.83 million units at $1.2775 | Apr 2, 2026 |
| ONCO | PRESS-RELEASE, 425 | mixed | 6/10 | Onconetix shared a press release from Realbotix, the target of its pending all-stock acquisition, announcing expected de | Apr 2, 2026 |
| ABEO | PRESS-RELEASE | neutral | 3/10 | Abeona Therapeutics announced the activation of NewYork-Presbyterian/Columbia University Irving Medical Center as its fi | Apr 2, 2026 |
| PSTV | PRESS-RELEASE | bullish | 6/10 | Plus Therapeutics announced a payer coverage agreement with Highmark, effective April 1, 2026, for its CNSide® CSF tumor | Apr 2, 2026 |
| ADAG | PRESS-RELEASE | neutral | 5/10 | Adagene priced a public offering of 18.7M ADSs at $3.75 per share, raising approximately $70.0 million in gross proceeds | Apr 2, 2026 |
| CATX | PRESS-RELEASE | neutral | 2/10 | Perspective Therapeutics announced upcoming investor presentations at two biopharma conferences in mid-April 2026. The f | Apr 2, 2026 |
| ADAG | PRESS-RELEASE | bullish | 7/10 | Adagene announced a clinical collaboration with Incyte to evaluate its masked anti-CTLA-4 therapy muzastotug in combinat | Apr 2, 2026 |
| SKYE | PRESS-RELEASE | mixed | 6/10 | Skye Bioscience has dosed the first patient in the Part C expansion of its Phase 2a trial for nimacimab, testing higher | Apr 2, 2026 |
| ADAG | PRESS-RELEASE | bullish | 8/10 | Adagene announced updated Phase 1b/2 data for muzastotug in advanced MSS CRC, showing a 31% confirmed ORR at 20 mg/kg, m | Apr 2, 2026 |
| PHVS | PRESS-RELEASE | neutral | 4/10 | Pharvaris reported a narrow EPS beat of 3% ($-0.60 vs $-0.62 consensus) with no revenue, typical for a pre-revenue biote | Apr 2, 2026 |
| ROIV | PRESS-RELEASE | bullish | 7/10 | Roivant Sciences' subsidiary Priovant has initiated a seamless Phase 2b/3 trial for brepocitinib in lichen planopilaris | Apr 2, 2026 |
| ROIV | PRESS-RELEASE | mixed | 6/10 | Roivant announced a new Phase 2b/3 trial for brepocitinib in lichen planopilaris (LPP), a rare scarring hair loss condit | Apr 2, 2026 |
| CLDX | PRESS-RELEASE | neutral | 5/10 | Celldex Therapeutics priced a public offering of 10,345,000 shares at $29.00 per share, raising approximately $300 milli | Apr 1, 2026 |
| CLDX | PRESS-RELEASE | neutral | 4/10 | Celldex Therapeutics announced a public offering of its common stock, with underwriters granted a 30-day option to purch | Apr 1, 2026 |
| NTHI | PRESS-RELEASE | mixed | 6/10 | NeOnc Technologies reported Q4 2025 earnings with a widened net loss of $62.1M, driven by higher G&A and R&D expenses, w | Apr 1, 2026 |
| ONMD | PRESS-RELEASE | neutral | 4/10 | OneMedNet announced a pilot collaboration with Inka Health, a subsidiary of Onco-Innovations, granting access to its iRW | Apr 1, 2026 |
| VIVS | PRESS-RELEASE | bearish | 6/10 | VivoSim Labs announced the pricing of a $4 million best-efforts public offering, with $3 million expected at an initial | Apr 1, 2026 |
| QNTM | PRESS-RELEASE | mixed | 6/10 | Quantum BioPharma (QNTM) announced the submission of an Investigational New Drug (IND) application to the FDA for Lucid- | Apr 1, 2026 |
| COGT | PRESS-RELEASE | bullish | 8/10 | Cogent Biosciences announced the submission of a New Drug Application (NDA) for bezuclastinib in second-line GIST under | Apr 1, 2026 |
| SNYR | PRESS-RELEASE | bearish | 7/10 | Synergy CHC Corp. reported a significant year-over-year decline in revenue and substantial net losses for both Q4 and fu | Apr 1, 2026 |
| MDCX | PRESS-RELEASE | bullish | 7/10 | Medicus Pharma clarified its Phase 2 topline data for SkinJect-003 in nodular basal cell carcinoma, emphasizing strong a | Apr 1, 2026 |
| INKT | PRESS-RELEASE | neutral | 3/10 | MiNK Therapeutics announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, in combination | Apr 1, 2026 |